XOMAP vs DBVT vs IMVT vs ABBV

For growth investors, XOMA Corporation (XOMAP) is the stronger pick with 83.

1% revenue growth year-over-year, versus 8. 6% for AbbVie Inc. (ABBV). XOMA Corporation (XOMAP) offers the better valuation at 17. 3x trailing P/E (22. 5x forward), making it the more compelling value choice. Analysts rate XOMA Corporation (XOMAP) a "Buy" — based on 9 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, XOMA Corporation (XOMAP) is the cheapest at 17.

3x versus AbbVie Inc. at 85. 5x. On forward P/E, AbbVie Inc. is actually cheaper at 14. 3x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, AbbVie Inc.

(ABBV) delivered a total return of +101. 3%, compared to -69. 1% for DBV Technologies S. A. (DBVT). Over 10 years, the gap is even starker: ABBV returned +295. 5% versus DBVT's -87. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), XOMA Corporation (XOMAP) is the lower-risk stock at 0.

03β versus Immunovant, Inc. 's 1. 37β — meaning IMVT is approximately 3976% more volatile than XOMAP relative to the S&P 500. On balance sheet safety, Immunovant, Inc. (IMVT) carries a lower debt/equity ratio of 0% versus 127% for XOMA Corporation — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), XOMA Corporation (XOMAP) is pulling ahead at 83.

1% versus 8. 6% for AbbVie Inc. (ABBV). On earnings-per-share growth, the picture is similar: XOMA Corporation grew EPS 188. 5% year-over-year, compared to -347. 5% for DBV Technologies S. A.. Over a 3-year CAGR, XOMAP leads at 105. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

XOMA Corporation (XOMAP) is the more profitable company, earning 60.

8% net margin versus 0. 0% for Immunovant, Inc. — meaning it keeps 60. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ABBV leads at 32. 8% versus 0. 0% for IMVT. At the gross margin level — before operating expenses — XOMAP leads at 94. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, AbbVie Inc.

(ABBV) trades at 14. 3x forward P/E versus 22. 5x for XOMA Corporation — 8. 3x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for DBVT: 131. 8% to $46. 33.

In this comparison, ABBV (3.

2% yield), XOMAP (1. 2% yield) pay a dividend. DBVT, IMVT do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, XOMA Corporation (XOMAP) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

03), 1. 2% yield). Both have compounded well over 10 years (XOMAP: +50. 9%, DBVT: -87. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: XOMAP is a small-cap high-growth stock; DBVT is a mega-cap quality compounder stock; IMVT is a small-cap quality compounder stock; ABBV is a large-cap income-oriented stock. XOMAP, ABBV pay a dividend while DBVT, IMVT do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.